Biotech Values

[DewDiligence]

I’m not examining the situation with that degree of granularity. The salient point is simply that Copaxone could be a rare case where a branded drug continues to be detailed even after it goes generic, which indirectly benefits the company selling the generic. Such an outcome is more likely, IMO, if Laquinimod turns out to be a commercial lightweight.